CXCL10

Immutep Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022
GLOBE, PFS, Abstract, CMO, Serum, Immunotherapy, Dor, Merck, Society, MHC, ASCO, Merck & Co., IMM, PD-L1, NASDAQ, Key finding attacks, Patient, Assistant, CXCL10, Biomarker, Cancer, Immutep, ASX, Pembrolizumab, Conference, Immune system, Breast cancer, TPS, TH1, DCR, NSCLC, Autoimmune disease, Endpoint, ORR, SITC, Vaccine, Pharmaceutical industry, Medicine, MD

Todays presentation followed the abstract data that had been discussed at the SITC 2022 Press Conference on 8 November 2022.

Key Points: 
  • Todays presentation followed the abstract data that had been discussed at the SITC 2022 Press Conference on 8 November 2022.
  • Responses in TACTI-002 were seen across all PD-L1 expression levels and histologic types, including in patients with PD-L1 TPS less than 50%.
  • The deep and durable responses driven by efti plus pembrolizumab continue to be favorable with median DoR of 21.6 months.
  • ORR improved across all PD-L1 status groups by central assessment compared with data reported at the American Society of Clinical Oncologys (ASCO) Annual Meeting in June 2022.

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

Retrieved on: 
Wednesday, November 9, 2022
GLOBE, Head, Intellectual property, Patent, Carboplatin, B cell, Immunotherapy, APC, Technology, Family, MHC, Large-cell lung carcinoma, R, MHC II, Institute, Monocyte, HNSCC, NASDAQ, Antibody, Fast Track, LAG-3, CXCL10, SITC, Topotecan, Company, Immutep, Cancer, Immunology, ASX, Research, NK, Patient, Treatment, NSCLC, Autoimmune disease, CD8, FDA, Oxaliplatin, Pharmaceutical industry, Vaccine

SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345 and 10-2441425) entitled “Combined Preparations for the Treatment of Cancer” by the Japanese Patent Office and South Korean Patent Office, respectively.

Key Points: 
  • These new patents in Japan and South Korea were filed as divisional applications.
  • The patents protect Immuteps intellectual property relating to combination preparations comprising lead active immunotherapy candidate eftilagimod alpha (efti) and a chemotherapy agent which is oxaliplatin, carboplatin, or topotecan.
  • These new patents are notable because this family of patents protects a component of the triple combination therapy being evaluated in our INSIGHT-003 clinical trial.
  • We also have other families of patents and patent applications which add to the protective moat around this triple combination.

Chemomab Presents Clinical Data from Investigator-Initiated Study Showing CM-101 Reduced Inflammatory and Fibrogenesis-Related Biomarkers in Patients with Severe Lung Injury Derived from Covid-19

Retrieved on: 
Wednesday, November 9, 2022
Union, Lung, Systemic scleroderma, Serum, Skin, Extracellular matrix, CRP, Risk, Liver, CXCL10, Fibrosis, Hospital, Nature, SEC, Biomarker, Private Securities Litigation Reform Act, Pneumonia, TEL, Population, Administration, Cirrhosis, C-reactive protein, Trial of the century, Conditional sentence, Treatment, CXCL9, Forward-looking statement, Inflammation, COVID-19, Scleroderma, PSC, Communication, CCL24, Conference, Nasdaq, Primary sclerosing cholangitis, Marketing, Research, Therapy, Safety, Adult, CMMB, Cytokine, Pharmaceutical industry, Silviculture, Patient

TEL AVIV, Israel, Nov. 9, 2022 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, announced that clinical data presented today showed that CM-101 was safe and well-tolerated and achieved reductions in biomarkers associated with lung inflammation and fibrogenesis in a clinical study in patients hospitalized with COVID-19-derived lung injury. CM-101 is a first-in-class monoclonal antibody that neutralizes CCL24, a soluble protein with pro-fibrotic and pro-inflammatory effects. It is in development for the treatment of fibro-inflammatory disorders, including primary sclerosingcholangitis (PSC) and systemic sclerosis (SSc).

Key Points: 
  • The presentation, Treatment with CM-101 Reduced Inflammatory & Fibrotic Biomarkers in Patients with COVID-19-Derived Lung Damage, was discussed by Chemomab co-founder and Chief Scientific Officer Dr. Adi Mor at the Union World Conference on Lung Health 2022.
  • The objective of the study was to evaluate the drug's safety and activity in hospitalized COVID-19 patients with severe pneumonia, including its impact on biomarkers related to lung inflammation that are also relevant in systemic sclerosis.
  • The open label, single arm trial enrolled 16 adult COVID-19 patients with severe respiratory involvement.
  • CM-101 exposures and target engagement profiles were similar to what Chemomab researchers have seen in previous clinical studies of CM-101.

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

Retrieved on: 
Friday, November 4, 2022
Immutep, HNSCC, CXCL10, Company, Immunology, MHC II, Antibody, FDA, B cell, CD8, NSCLC, NK, Poster, Large-cell lung carcinoma, APC, Head, Fast track (FDA), MHC, Autoimmune disease, Technology, LAG-3, Monocyte, Immunotherapy, Patient, Cancer, Pharmaceutical industry, Vaccine

SYDNEY, AUSTRALIA, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its late-breaking abstract titled “Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)” has been selected by the Society for Immunotherapy of Cancer (SITC) Communications Committee to be presented at the SITC 2022 Annual Meeting Press Conference.

Key Points: 
  • It also upregulates the expression of key biological molecules like CXCL10 that further boost the immune systems ability to fight cancer.
  • Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease.
  • Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immuteps large pharmaceutical partners.
  • Further information can be found on the Companys website www.immutep.com or by contacting:

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Retrieved on: 
Wednesday, November 2, 2022
Immutep, Immunotherapy, Large-cell lung carcinoma, CD8, Merck Sharp & Dohme Federal Credit Union, Monocyte, Immunology, Merck, Pembrolizumab, MHC, Fast track (FDA), Cancer, APC, B cell, Antibody, EST, Head, MHC II, CXCL10, Merck & Co., Technology, Investor, LAG-3, Company, FDA, Journal, Patient, NK, NSCLC, Autoimmune disease, HNSCC, Abstract (summary), Pharmaceutical industry, Vaccine

SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a late-breaking abstract relating to its phase II TACTI-002 trial has been accepted for an oral presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022. The oral presentation will include new clinical data for eftilagimod alpha (“efti”), its first-in-class soluble LAG-3 protein, in combination with pembrolizumab in 1st line non-small cell lung cancer (NSCLC) patients. The 37th Annual SITC meeting will be held in Boston, MA and virtually from 8 to 12 November 2022.

Key Points: 
  • Abstracts for all three presentations will be available in a Journal for ImmunoTherapy of Cancer Supplement, which will be published on 7 November 2022 at 8 am EST.
  • The Abstracts will also be subsequently made available on the Investors section of Companys website under Presentations .
  • It also upregulates the expression of key biological molecules like CXCL10 that further boost the immune systems ability to fight cancer.
  • Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease.

Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients

Retrieved on: 
Wednesday, September 7, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Spirometry, University, COVID-19, LSE, CEO, Safety, AIM, Protein, BCSS, US Food Sovereignty Alliance, HRV, Shortness of breath, Incidence, Degenerative disease, Bacteria, CXCL10, Food, Inhalation, Lung, Infection, Sputum, Cell, Severe acute respiratory syndrome coronavirus 2, Chronic obstructive pulmonary disease, Patient, FDA, COPD, Asthma, MHRA, Cough, Congress, Drug discovery, University of Southampton, CRP, Pharmaceutical industry, Medical imaging, Antibiotics, EU, Synairgen

In early 2020, due to the emergence of SARS-CoV-2, Synairgens SG015 trial in COPD patients was paused with 109 out of the targeted 120 patients recruited.

Key Points: 
  • In early 2020, due to the emergence of SARS-CoV-2, Synairgens SG015 trial in COPD patients was paused with 109 out of the targeted 120 patients recruited.
  • In the second week of treatment, a greater proportion of patients in the placebo group had purulent sputum or elevated serum CRP.
  • In 2018 Synairgen commenced a two-part COPD trial (SG015; NCT03570359) to assess initially, the safety and lung antiviral biomarker responses to SNG001 in the absence of viral infection.
  • In the first part of the trial SNG001 was well tolerated in patients with moderate to severe COPD.

A New T-Cell activation assay based on Hyris qPCR Technology marks a disruptive approach for the detection of SARS-CoV-2 specific cellular immunity

Retrieved on: 
Wednesday, June 15, 2022
Antibody, Doctor of Philosophy, Solution, European Review for Medical and Pharmacological Sciences, Population, Infection, COVID-19, Omicron, Vaccine, Technology, CXCL10, CEO, Nephrology, Research, Peptide, Manuscript, Disease, Severe acute respiratory syndrome coronavirus 2, Molecular biology, ELISpot, Death, Pathology, Assistant, Duke–NUS Medical School, Degenerative disease, PCR, Italy, GLOBE, RNA transfection, Pharmaceutical industry, Nature Biotechnology, Medicine, Genetics

With more than 10 billion total vaccine doses administered worldwide, vaccination campaigns have already started to attenuate this global crisis .

Key Points: 
  • With more than 10 billion total vaccine doses administered worldwide, vaccination campaigns have already started to attenuate this global crisis .
  • In order to maximize vaccine effectiveness, the efficacy and duration of protective immunity will need to be systematically assessed and monitored as widely as possible.
  • A team of internationally renowned medical scientists recently published a related paper in Nature Biotechnology , addressing the efficacy and sensitivity of a new type of assay to detect SARS-CoV-2 cellular immunity.
  • "Both the humoral (antibodies) and cellular immune response act in coordination to achieve long-term protection from viral infections.

Ventus Therapeutics Awarded Grant by the U.S. Department of Defense to Study the Role of cGAS in Lupus

Retrieved on: 
Monday, May 9, 2022
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Dermatomyositis, NLRP3, COVID-19, Scar, SLE, RNA, Pain scale, National Center for Advancing Translational Sciences, IFN, UVB, U.S. Department of Defense Strategy for Operating in Cyberspace, Sunlight, Â, Tooth discoloration, Patient, DNA, DM, Infant, Inflammation, LRP, Hypersensitivity, Human, Bureau of Oceans and International Environmental and Scientific Affairs, Therapy, Industry, Cytoplasm, Lupus, AGS, Neurology, Veteran, Quality of life, LinkedIn, Disease, Rockefeller University, Hair loss, Molecular biology, Technology, Protein, Research, Resolve, CXCL10, CLE, United States Department of Defense, DOD, Pharmaceutical industry, Vaccine, Ventus

The multi-year grant will be used to study the role of the DNA sensor, cyclic GMP-AMP synthase (cGAS), in lupus and the potential for treatment using a cGAS inhibitor.

Key Points: 
  • The multi-year grant will be used to study the role of the DNA sensor, cyclic GMP-AMP synthase (cGAS), in lupus and the potential for treatment using a cGAS inhibitor.
  • Systemic Lupus Erythematosus (SLE) is a chronic multi-organ auto-inflammatory disease for which there remains a high unmet medical need.
  • This susceptibility affects up to 70% of patients and can result in painful skin lesions that cause scarring, hair loss and discoloration.
  • The Lupus Research Program (LRP) was initiated in 2017 to provide support for research of exceptional scientific merit leading to a cure for lupus.

Immutep Presents New and Significant Data from the AIPAC Study

Retrieved on: 
Wednesday, May 4, 2022
Immune system, Breast cancer, NASDAQ, GLOBE, Monocyte, Biomarker, OS, Autoimmune disease, Patient, Immunotherapy, ALC, Survival, CD8, Cancer, Paclitaxel, Blood, CD4, CMO, IMM, Serum, CXCL10, SITC, AIPAC, ASX, Vaccine, Pharmaceutical industry

The data was presented at ESMOs Breast Cancer Congress in a poster presentation which is available on ESMOs website and at https://www.immutep.com/investors-media/presentations.html .

Key Points: 
  • The data was presented at ESMOs Breast Cancer Congress in a poster presentation which is available on ESMOs website and at https://www.immutep.com/investors-media/presentations.html .
  • Final OS results were reported in November 2021 in a late breaking abstract at SITC showing encouraging efficacy in multiple patient subgroups.
  • Dr Frederic Triebel, Immuteps CSO and CMO said: The biomarker analysis is highly valuable for two key reasons.
  • Firstly, the statistically significant difference in the immune response between the efti and placebo patients confirms efti is activating the immune system and helping patients live longer.

ChemoCentryx Reports Pharmacokinetic and Pharmacodynamic Results from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Wednesday, April 13, 2022
Patient, News, Cancer, Poster, Pharmacodynamics, Medication, Pharmacokinetics, PK, U.S. Securities and Exchange Commission, Association, ANCA, Adult, Achievement, Security (finance), CD8, Hidradenitis suppurativa, CXCL9, CD80, Annual report, PD-1, Half-life, PD-L1, Private Securities Litigation Reform Act, GLOBE, Risk, Terminology, Goal, CXCL10, SAN, Progress, HS, Full, Plasma, Nasdaq, Company, CD4, SEC, Kinetics, American Association for Cancer Research, Degenerative disease, Safety, American Association, AACR, PD, Pharmaceutical industry, Palladium

SAN CARLOS, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the presentation of preclinical data and initial pharmacokinetic (PK) and pharmacodynamic (PD) data from the ongoing Phase I clinical study of CCX559 during a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Key Points: 
  • The PD-L1/PD-1 interaction is one of the major immune checkpoints that limits the ability of effector T cells to destroy cancer cells.
  • During 2021, ChemoCentryx initiated a first-in-human Phase I dose escalation study to evaluate the safety, tolerability, PK and PD of CCX559 in patients with various types of advanced cancer.
  • In this Phase I basket study, CCX559 is taken orally once per day at specified dose levels, starting at 30 mg and ranging to date to 120 mg.
  • ChemoCentryx expects to present additional findings from this ongoing Phase I study at major oncology conferences through 2022.